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Identity 
Other names: PSOR1, S100A7c 
HGNC (Hugo): S100A7 
Location: 1q21.3 
Local order: S100A7 is located on chromosome 1cen-
q21 between D1Z5 and MUC1 (Borglum et al., 1995). 
Note: S100A7 is also known as psoriasin, psoriasin 1, 
S100 calcium binding protein A7, S100-A7, S100A7c, 
and PSOR1. 
S100A7, a member of the S100 family, was first 
identified as a protein upregulated in psoriasis (Madsen 
et al., 1991). 
DNA/RNA 
Note 
S100A7 is located on chromosome 1q21 within the 
epidermal differentiation complex. 
Description 
The S100A7 gene has 3 exons and 2 introns with a  
genomic structure similar to other S100 family 
members. Exon 1 encodes the 5' untranslated region 
while exons 2 and 3 contain the protein coding 
sequence. Exon 2 encodes the start codon and the non-
canonical N-terminal EF-hand while exon 3 encodes 
the carboxyl-terminal EF-hand. 
Transcription 
The S100A7 gene encodes for a single constitutively 
spliced transcript. An EST has been reported in which 
an alternative promoter is used to produce an identical 
S100A7 mRNA (See Ensembl, UCSC genome 
browser). 
Pseudogene 
Five copies of S100A7 in the human genome have been 
reported including the closely related paralog S100A15 
(also known as S100A7A) (Kulski et al., 2003; Wolf et 
al., 2003). Two of the five reported copies of S100A7, 
S100A7d (S100A7P1) and S100A7e (S100A7P2), are 
proposed to be non-coding pseudogenes (Kulski et al., 
2003; Marenholz et al., 2006). 
 
The S100A7 genomic organization includes 3 exons and 2 introns with exons 2 and 3 containing the protein encoding sequence 
(Semprini et al., 1999). The EF-hand domains are highlighted (Burgisser et al., 1995). 
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A. S100A7 primary sequence highlighting the calcium- and zinc-binding residues and the EF-hand domains. 
 
 




S100A7 is a member of the S100 family of calcium-
binding signaling proteins. S100A7 has both 
intracellular and extracellular functions. 
Description 
S100A7 is a small 11.4 kDa protein containing a C-
terminal canonical calcium-binding EF-hand motif and 
an N-terminal non-canonical EF-hand motif which is 
characteristic of the S100 protein family. S100A7 
forms a homodimer with one Ca
2+
 ion bound by the 
canonical EF-hand motif in each monomer and two 
Zn
2+
 ions located at the dimer interface (Brodersen et 
al., 1999). S100A7 monomers and putative higher order 
multimers have been observed in both psoriatic and 
healthy epidermis (Ruse et al., 2001). 
Expression 
S100A7 is present at low levels in healthy skin, 
however it is highly upregulated in psoriatic epidermal 
keratinocytes (Madsen et al., 1991). E. Coli has been 
shown to induce S100A7 expression in keratinocytes 
(Gläser et al., 2005). 
S100A7 expression is upregulated in several cancers 
including skin, breast, lung, head, neck, cervix, bladder 
and gastric cancer (for review see Emberley et al., 
2004). 
S100A7 expression is induced in MCF10 cells by 
stresses such as serum deprivation and cell confluency 
(Enerback et al., 2002). 
S100A7 is repressed by BRCA1 in a c-myc dependent 
manner in HCC-BR116 cells (Kennedy et al., 2005). 
17beta-estradiol treatment increased S100A7 
expression in an estrogen receptor beta dependent 
manner in MCF-7 cells (Skliris et al., 2007). Epidermal 
Growth Factor induces S100A7 expression in MCF-7 
and MDA-MB-468 cells (Paruchuri et al., 2008). 
S100A7 expression is induced by proinflammatory 
cytokines in skin and breast cancer cells. S100A7 
expression is enhanced in human keratinocytes by 
stimulation with the cytokine IL-22 in combination 
with IL-17 or IL-17F (Liang et al., 2006). Oncostatin-
M was shown to induce S100A7 expression in human 
epidermal cell skin equivalents (Gazel et al., 2006). 
S100A7 expression is induced by the cytokines 
oncostatin-M and IL-6 in MCF-7, TD47 and MDA-
MB-468 cell lines (West and Watson, 2010). 
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Localisation 
S100A7 is localized to the cytoplasm, nucleus, cell 
periphery and is also secreted from cells.  
In keratinocytes, S100A7 is observed in the cytoplasm 
when untreated and at the cell periphery upon 
stimulation with calcium (Ruse et al., 2003). S100A7 is 
expressed at low levels or is not detected in healthy 
breast cells. In breast cancer cells, however, S100A7 is 
observed in the nucleus and cytoplasm and is also 
secreted (Al-Haddad et al., 1999; Enerback et al., 
2002). 
Function 
S100A7 has been shown to function as a chemotactic 
factor for neutrophils and CD4+ T cells (Jinquan et al., 
1996). S100A7 binds RAGE (receptor for advanced 
glycation end products) in a zinc-dependent manner 
and is proposed to mediate chemotaxis in a RAGE-
dependent manner (Wolf et al., 2008). S100A7 present 
in skin functions as a Zn-dependent antimicrobial 
towards E.Coli (Glaser et al., 2005). S100A7 has also 
been shown to play an antibacterial role in wound 
healing (Lee and Eckert, 2007). S100A7 is a substrate 
for transglutaminase (Ruse et al., 2001). 
S100A7 interacts, co-purifies and colocalizes in the 
cytoplasm with epidermal-type fatty acid-binding 
protein (E-FABP), a protein which is also upregulated 
in psoriasis (Hagens et al., 1999; Ruse et al., 2003). 
S100A7 has been shown to interact with RanBPM by 
yeast two-hybrid and co-immunoprecipitation studies 
in breast cancer cells (Emberley et al., 2002). S100A7 
has been shown to interact with the multifunctional 
signalling protein, Jab1, yeast two-hybrid and co-
immunoprecipitation studies in breast cancer cells 
(Emberley et al., 2003). The Jab1-S100A7 interaction 
and downstream effects were disrupted by mutation of 
a Jab1-binding site (Emberley et al., 2003; West et al., 
2009). 
Homology 
S100A7 is a member of the S100 family of vertebrate 
proteins. Among the S100 family, S100A7 is the most 
divergent (Burgisser et al., 1995) with the exception of 
a recently identified paralog S100A715 (or S100A7A), 
with which it shares 93% similarity (Wolf et al., 2003). 
A bovine ortholog to S100A7, Bosd3 (Virtanen, 2006) 
and equine ortholog (Leeb et al., 2005) have also been 
reported. The mouse S100A7, which has 40% 
similarity (Webb et al., 2005), has been assigned the 
designation mouse S100A15 (Wolf et al., 2006). 
Mutations 
Note 
An allergy associated polymorphism of S100A7 





Psoriasis and other skin diseases 
Note 
S100A7 is associated with inflammation in several skin 
diseases (Algermissen et al., 1996). S100A7 was 
originally identified as a protein secreted from psoriatic 
skin (Madsen et al., 1991). S100A7 is also 
overexpressed in skin lesions of patients with lichen 
sclerosus (Gambichler et al., 2009), acne inversa 
(Schlapbach et al., 2009), and middle ear cholesteatoma 
(Kim et al., 2009). 
Non-melanoma skin cancer 
Note 
S100A7 may play a role in the progression of skin 
cancer. S100A7 expression is not observed in healthy 
epidermis. When S100A7 levels were studied by 
immunohistochemistry in squamous cell carcinoma 
skin lesions, higher levels of expression were found in 
pre-invasive squamous cell carcinoma in situ compared 
to invasive squamous cell carcinoma (Alowami et al., 
2003). In a separate study, S100A7 mRNA levels, 
determined by real-time PCR, were upregulated in pre-
cancerous skin lesions and epithelial skin tumours 
including basal cell carcinoma and squamous cell 
carcinoma (Moubayed et al., 2007). 
Melanoma 
Note 
S100A7 protein was observed at higher levels in the 
urine of melanoma patients compared to healthy 
controls (Brouard et al., 2002), although S100A7 was 
not detected in melanoma cells (Petersson et al., 2009). 
Ductal carcinoma in situ (DCIS) and 
breast cancer 
Note 
S100A7 was first associated with primary breast cancer 
(Moog-Lutz et al., 1995). Later studies identified 
S100A7 as one of the most highly expressed genes in 
DCIS, a key stage before the transition to invasive 
breast cancer (Leygue et al., 1996; Enerback et al., 
2002). When S100A7 is expressed in later stages of 
breast cancer it is associated with the agressive 
estrogen-negative tumors and poor prognosis (Al-
Haddad et al., 1999; Emberley et al., 2004). In vivo 
mouse model studies have shown that S100A7 
promotes tumorigenesis (Emberley et al., 2003; Krop et 
al., 2005). Several of the tumorigenic effects of 
S100A7, including upregulation of NF-kappaB, PI3K-
Akt, and AP-1 as well as promotion of cell survival, are 
mediated by the interaction of S100A7 with Jab1 










Atlas Genet Cytogenet Oncol Haematol. 2011; 15(1)  62 
Epithelial ovarian cancer 
Note 
S1007 mRNA and protein levels are upregulated in 
epithelial ovarian carcinoma tissue compared to normal 
and benign ovary tissue (Gagnon et al., 2008). 
Autoantibodies to S100A7 were detected at higher 
levels in the plasma of early and late-stage ovarian 
cancer patients compared to healthy controls (Gagnon 
et al., 2008). S100A7 autoantibodies may be useful as a 
biomarker for epithelial ovarian cancer (for review see 
Piura and Piura, 2009). 
Lung squamous cell carcinoma 
Note 
S100A7 is associated with non-small lung squamous 
cell carcinoma metastasis to the brain (Zhang et al., 
2007). Proteomic studies identified S100A7 as a 
protein upregulated in a brain metastasis lung 
squamous cell carcinoma cell line and S100A7 
overexpression was confirmed in brain metastasis 
tissues (Zhang et al., 2007). 
Bladder squamous cell carcinoma 
Note 
S100A7 was detected in bladder squamous cell 
carcinoma tumors and also in the urine of patients with 
bladder squamous cell carcinoma (Celis et al., 1996; 
Ostergaard et al., 1997). As a result, S100A7 has been 
proposed to be a potential biomarker for bladder 
squamous cell carcinoma (Celis et al., 1996; Ostergaard 
et al., 1997; Ostergaard et al., 1999). 
Oral squamous cell carcinoma 
Note 
S100A7 is associated with oral squamous cell 
carcinoma (Zhou et al., 2008; Kesting et al., 2009). RT-
PCR and immunofluorescence studies showed that 
S100A7 mRNA and protein levels respectively are up-
regulated in oral squamous cell carcinoma tissues 
compared to normal oral tissues (Kesting et al., 2009). 
Head-and-neck squamous cell 
carcinoma 
Note 
S100A7 is a highly upregulated biomarker in head-and-
neck squamous cell carcinomas (Ralhan et al., 2008). 
Gastric cancer 
Note 
SAGE (serial analysis of gene expression) studies 
identified S100A7 as one of the top twenty genes 
upregulated in gastric cancer (El-Rifai et al., 2002). 
Further mining of publicly available SAGE, virtual 
Northern Blot, and microarray data confirmed the 
association of S100 proteins such as S100A7 with 




Chronic rhinosinusitis (CRS) is characterized by a 
persistant inflammation of the nasal mucosa. It has 
been proposed that the antibacterial function of 
S100A7 play a role in protecting against the 
environmental factors that contribute to chronic 
rinosinusitis (for review see Tieu et al., 2009). Reduced 
levels of S100A7 were detected in the nasal lavage 
fluid of patients with allergic rhinitis when compared to 
controls (Bryborn et al., 2005). A polymorphism 
(RS3014837) has been linked with allergic individuals 
in Sweden (Bryborn et al., 2008). 
Systemic sclerosis (SSc) 
Note 
S100A7 is upregulated in the saliva of patients with 
systemic sclerosis when compared to healthy 
individuals and has been proposed as a potential 
biomarker for systemic sclerosis with pulmonary 
involvement (Giusti et al., 2007; Baldini et al., 2008). 
Alzheimer's disease 
Note 
A recent study has suggested that S100A7 is a potential 
biomarker for Alzheimer's disease. Increased levels of 
S100A7 were detected in the cerebralspinal fluid and 
brain of patients with Alzheimer's disease (Qin et al., 
2009). 
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